Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017)

Doganis, Dimitrios; Zborovskaya, A.; Trojanowski, Maciej; Žagar, Tina; Bouka, Panagiota; Baka, Margaret; Moschovi, Maria; Polychronopoulou, Sofia; Παπακωνσταντίνου, Ευγενία; Tragiannidis, Athanasios; Stiakaki, Eftichia; Dana, Helen; Stefanaki, Kalliopi; Strantzia, Katerina; Kochubinsky, D. V.; Marciniak, Patrycja; Avčin, Simona Lucija; Antoniadi, Kondilia; Dessypris, Nick; Petridou, Eleni

doi:10.1016/j.ejca.2019.04.008

Cited by 16 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 1 girl remains in remission, in the other 2 cases the course of the treatment was complicated with recurrences, and intensive treatment gave many side effects and ended with failure. Data from Southern and Eastern Europe state that high-risk or unfavourable histology cases have 2.3 times higher relapse rate and 5.6 times higher respective death rate than low and intermediate risk groups or favourable histology cases [6].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Characteristics of patients with blastemal-type Wilms’ tumour

Hajzler¹,

Kopera²,

Kosek³

et al. 2021

polp

View full text Add to dashboard Cite

Wilms' tumour (nephroblastoma) is the most common malignant tumour of kidney in children and one of the 2 most common solid tumours located outside of the central nervous system. Nephroblastoma has a very good prognosis, but some histological types like blastemal-type require qualification to a high-risk group and intensification of treatment. We present the cases of 3 children diagnosed with nephroblastoma, blastemal-type. The first girl's treatment was unsuccessful, as there were 4 cancer recurrences. The second girl had primarily metachronous form of nephroblastoma, but during recurrence the blastemal-type was diagnosed. Despite intensive treatment, it ended with failure. The third girl had a tumour in the left kidney, which was transformed from the bilateral nephroblastomatosis. She remains in remission; the therapy ended on February 2018.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Blastemal-type tumour consists of over 66% of blastemal cells in a tumour with more than 33% of cells viable [4]. Blastemal cells respond poorly to treatment, which is associated with greater risk of recurrence and lower EFS and OS rates [6][7][8]. In this article we presented 3 cases of patients diagnosed with blastemal-type Wilms' tumours.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of patients with blastemal-type Wilms’ tumour

Hajzler¹,

Kopera²,

Kosek³

et al. 2021

polp

View full text Add to dashboard Cite

show abstract

“…In the neoadjuvant setting, or for hematologic malignancies or other settings where interventions such as drugs, biologics, radiation therapy, or surgery would be used to render a patient free of detectable disease after a well-defined induction/neo-adjuvant period, a logical extension of the validated concept of DFS would be a time-to-event endpoint, with failure defined to be the earliest of the occurrence of: (a) failure to achieve disease-free status locally at the end of the induction and surgery period; (b) detection of recurrence of disease (either local post induction or distal) by CT; or (c) death. 6,[11][12][13] Figure 1 provides a graphical summary of this definition of EFS. This composite endpoint, which is a novel formulation of DFS applied in the neoadjuvant setting, seems particularly well suited to be a key measure of efficacy for therapeutic strategies in settings such as LAPC that may involve neoadjuvant treatment followed by surgery, with the goal of rendering such patients disease-free (locally and systemically).…”

Section: Formulating a Novel Event-free Survival Endpoint For Lapcmentioning

confidence: 99%

A novel event-free survival endpoint in locally advanced pancreatic cancer

et al. 2021

View full text Add to dashboard Cite

The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS) are presently being pursued. These efforts justify re-visiting study endpoints in order to better predict therapeutic effects on OS, by capturing not only the achievement of R0 resection at the end of induction therapy but also the long-term reductions in the rate of local and distal recurrence. The proposed herein event-free survival (EFS) endpoint, with its novel definition specific to LAPC, is formulated to achieve these objectives. It is an analog to disease-free survival (DFS) endpoint in the adjuvant setting applied to the neoadjuvant setting and may be a valuable surrogate endpoint for this patient population.

show abstract

“…In the US, clear cell sarcoma of kidney (CCSK) comprises ∼2-4% of all primary childhood renal tumors (1)(2)(3). Clinical features and treatment protocols of CCSK have been widely studied (4)(5)(6)(7)(8)(9); however the epidemiology (e.g., incidence rate) is seldom described. The database that pooled 59 population-based cancer registries in 19 European countries demonstrated an age-adjusted incidence of 0.2 per million among children aged 0-14 years during the period 1978-1997, and CCSK ranked second in all childhood renal tumors (10).…”

Section: Introductionmentioning

confidence: 99%

Childhood Clear Cell Sarcoma of Kidney: Incidence and Survival

et al. 2021

View full text Add to dashboard Cite

This study is to describe current incidence of childhood clear cell sarcoma of kidney (CCSK) and to investigate the present survival of this cancer. Surveillance, Epidemiology, and End Result (SEER) data was used to identify children with CCSK and Wilms tumor (WT) aged 0–19 years in the US. Age-adjusted incidences were estimated over the decades. Age- and sex-specific epidemiology was also presented. Propensity score matching was used to balance features of CCSK and WT cases. Log rank test was used to compare survivals and Cox regression was used to evaluate independent effects of factors. The present age-adjusted incidence of childhood CCSK was 0.205 per million, which remained stable for years and ranked third in all pediatric renal tumors. The incidence rate ratios for boy and age under 4 were 3 and 21, respectively. The current 5-year overall survival (OS) rate for CCSK was 87%, which is not evidently inferior to that for WT (90%); however the outcome of CCSK was significantly poorer if both groups were well-balanced (OS rate was 86 vs. 95%). Early year of diagnosis and distant metastasis were independent survival factors. In conclusion, occurrence of CCSK remains stable over the years, with an age-adjusted incidence of 0.205 per million. Boy and age under 4 are risk factors for tumor development. CCSK currently has a favorable outcome but its nature may be more aggressive than common kidney tumor, which in turn proves efficacy of modern treatment.

show abstract

Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017)

Cited by 16 publications

References 35 publications

Characteristics of patients with blastemal-type Wilms’ tumour

Characteristics of patients with blastemal-type Wilms’ tumour

A novel event-free survival endpoint in locally advanced pancreatic cancer

Childhood Clear Cell Sarcoma of Kidney: Incidence and Survival

Contact Info

Product

Resources

About